Advanced Oxygen Therapy

The company's TWO2 Topical Wound Oxygen therapy has demonstrated significant clinical benefits in randomized controlled trials and real-world evidence studies. It has been shown to reduce amputations by up to 71%, lower recurrence rates at one year by six-fold, and decrease hospitalizations and amputations compared to standard of care alone. The technology has received an "A-grade" adjunctive treatment recommendation from the American Diabetes Association for diabetic foot ulcers.

Studies within the VA population have shown a six-fold reduction in ulcer recurrence, nine-fold reduction in hospitalizations, and five-fold reduction in amputations over twelve months.

The product can be used at home or in healthcare facilities.

The company recently entered the Negative Pressure Wound Therapy market as well.

Thousands of patients have benefited from their therapies globally.

Regulatory clearances include FDA registration/compliance with Quality System Regulation CFR Part 820; ISO13485 certification; Health Canada registration; ACHC accreditation.

AOTI’s products are available internationally.

No specific drug development programs—focus on devices/technologies for wound healing.